More powerful breast cancer risk stratification for more personalized care
Give high-risk patients the most comprehensive risk assessment
For patients with a family history of certain cancers, MyRisk with RiskScore evaluates 48 genes associated with hereditary cancer risk to identify genetic changes associated with an increased cancer risk. When combined with family history and other clinical factors, MyRisk with RiskScore provides each patient with a comprehensive, personalized assessment of the five-year risk and remaining lifetime risk of developing breast cancer by combining personal and family history with breast cancer genetic risk markers and ancestry genetic markers. This makes MyRisk with RiskScore a powerful tool that helps you and your patients make more informed decisions to help prevent breast cancer or diagnose it at an earlier, more treatable stage.
How MyRisk with RiskScore uniquely stratifies risk to inform and personalize patient care
MyRisk with RiskScore: Improved risk stratification that’s 2x more predictive of breast cancer risk than Tyrer-Cuzick alone1,2
Over half of patients who test negative for a hereditary cancer syndrome will have a change in medical management due to their family history of cancer and/or their RiskScore3
Validated technology with results you can trust based on outcomes data from >130,000 patients1,2,4-7
The first and only comprehensive breast cancer risk assessment that includes breast density, clinical factors, and a polygenic risk score validated for patients acr oss all ancestries 4,6,8
How would you guide this patient’s breast cancer risk management?
Carmen 53 years old
Medical management
Annual mammograms
Results Normal mammogram
Using
other assessment, Carmen would have not met guidelines for a breast MRI, delaying her diagnosis and treatment.
Results
Normal mammogram
Abnormal breast MRI
Diagnosis
Subsequent biopsy revealed Stage II breast cancer
My surgeon asked me, ‘Why get the MRI when the mammogram was clear?’ The answer was simple: MyRisk with RiskScore. He replied, ‘When you see the doctor who recommended MyRisk, thank them. If you had waited another six months, we wouldn’t be having the same conversation.’ The type of cancer I had was so aggressive that if I hadn’t had the genetic testing, it may have been too late to save my life.”
— Patient testimonial
References:
1. Mabey B, Hughes E, Kucera M, et al. Validation of a clinical breast cancer risk assessment tool combining a polygenic score for all ancestries with traditional risk factors. GIM. 2024;26(7):101128-101128. doi:https://doi.org/10.1016/j.gim.2024.101128. 2. Hughes E, Tshiaba P, Wagner S, et al. Integrating clinical and polygenic factors to predict breast cancer risk in women undergoing genetic testing. JCO Precis. Oncol. 2021;(5):307-316. doi:10.1200/po.20.00246. 3. Myriad internal data based on MyRisk tests reported between 09/1/2021 and 02/01/2023 ordered for unaffected patients by OBGYN & Primary Care healthcare providers. 4. Hughes E, Wagner S, Pruss D, et al. Development and Validation of a Breast Cancer Polygenic Risk Score on the Basis of Genetic Ancestry Composition. JCO Precis. Oncol. 2022;(6). doi:https://doi.org/10.1200/po.22.00084. 5. Kurian AW, Hughes E, Simmons T, et al. Performance of the Ibis/tyrer-cuzick model of breast cancer risk by race and ethnicity in the Women’s Health initiative. Cancer. 2021;127(20):3742-3750. doi:10.1002/cncr.33767. 6. Kucera, Matthew, et al. Polygenic risk score calibration and association with breast cancer in diverse ancestries. Poster presented at American Society of Clinical Oncology Annual Meeting; 2023; Chicago, IL. 7. Hughes E, Tiemeny P, Gallagher S, et al. Ancestrally unbiased polygenic breast cancer (BC) risk assessment. J. Clin. Oncol. 2021;39(15_suppl):10502-10502. doi:10.1200/jco.2021.39.15_suppl.10502. 8. Hughes E, Probst B, Pederson HJ, et al. A breast cancer (BC) risk model incorporating Tyrer-Cuzick version 8 (TCV8) and a polygenic risk score (PRS) for diverse ancestries. J. Clin. Oncol. 2022;40(16_suppl):557-557. doi:10.1200/jco.2022.40.16_suppl.557. 9. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to Mammography. CA. 2007;57(2):75-89. doi:10.3322/canjclin.57.2.75.
